DOD Biotech Public Company Limited reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported sales was THB 163.88 million compared to THB 184.25 million a year ago. Revenue was THB 168.76 million compared to THB 185.38 million a year ago. Net income was THB 0.298591 million compared to THB 22 million a year ago. Basic earnings per share from continuing operations was THB 0.01. Diluted earnings per share from continuing operations was THB 0.01. Basic earnings per share was THB 0.001 compared to THB 0.054 a year ago. Diluted earnings per share was THB 0.001 compared to THB 0.054 a year ago.
For the nine months, sales was THB 458.37 million compared to THB 787.68 million a year ago. Revenue was THB 466.95 million compared to THB 789.4 million a year ago. Net loss was THB 36.98 million compared to net income of THB 19.29 million a year ago. Basic earnings per share from continuing operations was THB 0.034 compared to THB 0.487 a year ago. Diluted earnings per share from continuing operations was THB 0.034 compared to THB 0.487 a year ago. Basic loss per share was THB 0.09 compared to basic earnings per share of THB 0.047 a year ago. Diluted loss per share was THB 0.09 compared to diluted earnings per share of THB 0.047 a year ago.